Molecure appoints Lutostanski: Molecure stock costs EUR 1.40 before October 30

Published on 10/20/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half net loss fell to PLN 6.31 million. Molecure stock costs EUR 1.40 on October 20, 2026. The next report is due October 30, 2026.

Board change and clinical milestones

Piotr Lutostanski joined Molecure's supervisory board on October 6, 2026.
Operating revenue reached PLN 1.86 million in the first half of 2026.
Molecure stock traded at EUR 1.40 at 1:42 p.m. CEST on October 20, 2026 at Lang & Schwarz.

Molecure, PLONCTH00011, Illustration mit AI erstellt.

Molecure appointed Piotr Lutostanski to its supervisory board on October 6, 2026, while its next quarterly report is scheduled for October 30, 2026. The stock was quoted at EUR 1.40 at Lang & Schwarz on October 20, 2026 at 1:42 p.m. CEST. The board appointment was reported by GPW Alert.

Clinical timeline has three markers

Molecure's clinical program has added three dated markers. On May 28, 2026, the company dosed the first patient in the 80 milligram daily cohort of its OATD-02 Phase I study. On September 30, 2026, its OATD-01 KITE study had randomized more than 40 patients, according to Molecure. On October 6, 2026, Lutostanski joined the supervisory board, replacing Robert Oskard after his resignation.

What comes next for funding?

The October 30 report is the next scheduled company date, followed by the BIO Europe conference from November 9 to November 11, 2026. The first-half report gives investors a clear financial constraint: operating revenue was PLN 1.86 million, down from PLN 3.52 million in the first half of 2025, while net loss narrowed to PLN 6.31 million from PLN 8.52 million. Cash stood at PLN 24.91 million on June 30, 2026. These figures keep clinical execution and financing closely linked.

Clinical progress meets financial pressure

Molecure said operating costs fell by PLN 4.45 million year over year to PLN 8.20 million in the first half of 2026. The KITE study reached 30 patients during the first half, enabling its first planned interim analysis, while an independent monitoring committee recommended continuation in July 2026. The study remains blinded, so the company said the observations cannot yet establish treatment efficacy. The combination of more than 40 randomized patients and lower operating costs gives the October report two measurable benchmarks.

Stock quote and listing

The Warsaw Stock Exchange quote was last at PLN 6.15 on October 20, 2026 at 1:27 p.m. CEST. Molecure is a clinical-stage biotechnology company developing small-molecule drug candidates, with OATD-01 in Phase II and OATD-02 in Phase I.

The further course of trading is shown by the continuously updated real-time quote of Molecure stock.